Smoothened (SMO) receptor mutations dictate resistance tovismodegib in basal cell carcinoma

Sabrina Pricl, Barbara Cortelazzi, Valentina Dal Col, Domenico Marson, Erik Laurini, Maurizio Fermeglia, Lisa Licitra, Silvana Pilotti, Paolo Bossi, Federica Perrone

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Basal cell carcinomas (BCCs) and a subset of medulloblastomas are characterized by loss-of-function mutations in the tumor suppressor gene, PTCH1. PTCH1 normally functions by repressing the activity of the Smoothened (SMO) receptor. Inactivating PTCH1 mutations result in constitutive Hedgehog pathway activity through uncontrolled SMO signaling. Targeting this pathway with vismodegib, a novel SMO inhibitor, results in impressive tumor regression in patients harboring genetic defects in this pathway. However, a secondary mutation in SMO has been reported in medulloblastoma patients following relapse on vismodegib to date. This mutation preserves pathway activity, but appears to confer resistance by interfering with drug binding.Here we report for the first time on the molecular mechanisms of resistance to vismodegib in two BCC cases. The first case, showing progression after 2 months of continuous vismodegib (primary resistance), exhibited the new SMO G497W mutation. The second case, showing a complete clinical response after 5 months of treatment and a subsequent progression after 11 months on vismodegib (secondary resistance), exhibited a PTCH1 nonsense mutation in both the pre- and the post-treatment specimens, and the SMO D473Y mutation in the post-treatment specimens only. In silico analysis demonstrated that SMOG497W undergoes a conformational rearrangement resulting in a partial obstruction of the protein drug entry site, whereas the SMO D473Y mutation induces a direct effect on the binding site geometry leading to a total disruption of a stabilizing hydrogen bond network. Thus, the G497W and D473Y SMO mutations may represent two different mechanisms leading to primary and secondary resistance to vismodegib, respectively.

Original languageEnglish
Pages (from-to)389-397
Number of pages9
JournalMolecular Oncology
Volume9
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

HhAntag691
Basal Cell Carcinoma
Mutation
Medulloblastoma
Smoothened Receptor
Nonsense Codon
Tumor Suppressor Genes
Pharmaceutical Preparations
Computer Simulation
Hydrogen
Therapeutics
Binding Sites
Recurrence

Keywords

  • Basal cell carcinoma
  • Hedgehog pathway
  • Primary resistance
  • PTCH1
  • Secondary resistance
  • SMO
  • Vismodegib

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine
  • Medicine(all)

Cite this

Smoothened (SMO) receptor mutations dictate resistance tovismodegib in basal cell carcinoma. / Pricl, Sabrina; Cortelazzi, Barbara; Dal Col, Valentina; Marson, Domenico; Laurini, Erik; Fermeglia, Maurizio; Licitra, Lisa; Pilotti, Silvana; Bossi, Paolo; Perrone, Federica.

In: Molecular Oncology, Vol. 9, No. 2, 01.02.2015, p. 389-397.

Research output: Contribution to journalArticle

Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M et al. Smoothened (SMO) receptor mutations dictate resistance tovismodegib in basal cell carcinoma. Molecular Oncology. 2015 Feb 1;9(2):389-397. https://doi.org/10.1016/j.molonc.2014.09.003
Pricl, Sabrina ; Cortelazzi, Barbara ; Dal Col, Valentina ; Marson, Domenico ; Laurini, Erik ; Fermeglia, Maurizio ; Licitra, Lisa ; Pilotti, Silvana ; Bossi, Paolo ; Perrone, Federica. / Smoothened (SMO) receptor mutations dictate resistance tovismodegib in basal cell carcinoma. In: Molecular Oncology. 2015 ; Vol. 9, No. 2. pp. 389-397.
@article{4e298edb0a894d838334db8b19538f77,
title = "Smoothened (SMO) receptor mutations dictate resistance tovismodegib in basal cell carcinoma",
abstract = "Basal cell carcinomas (BCCs) and a subset of medulloblastomas are characterized by loss-of-function mutations in the tumor suppressor gene, PTCH1. PTCH1 normally functions by repressing the activity of the Smoothened (SMO) receptor. Inactivating PTCH1 mutations result in constitutive Hedgehog pathway activity through uncontrolled SMO signaling. Targeting this pathway with vismodegib, a novel SMO inhibitor, results in impressive tumor regression in patients harboring genetic defects in this pathway. However, a secondary mutation in SMO has been reported in medulloblastoma patients following relapse on vismodegib to date. This mutation preserves pathway activity, but appears to confer resistance by interfering with drug binding.Here we report for the first time on the molecular mechanisms of resistance to vismodegib in two BCC cases. The first case, showing progression after 2 months of continuous vismodegib (primary resistance), exhibited the new SMO G497W mutation. The second case, showing a complete clinical response after 5 months of treatment and a subsequent progression after 11 months on vismodegib (secondary resistance), exhibited a PTCH1 nonsense mutation in both the pre- and the post-treatment specimens, and the SMO D473Y mutation in the post-treatment specimens only. In silico analysis demonstrated that SMOG497W undergoes a conformational rearrangement resulting in a partial obstruction of the protein drug entry site, whereas the SMO D473Y mutation induces a direct effect on the binding site geometry leading to a total disruption of a stabilizing hydrogen bond network. Thus, the G497W and D473Y SMO mutations may represent two different mechanisms leading to primary and secondary resistance to vismodegib, respectively.",
keywords = "Basal cell carcinoma, Hedgehog pathway, Primary resistance, PTCH1, Secondary resistance, SMO, Vismodegib",
author = "Sabrina Pricl and Barbara Cortelazzi and {Dal Col}, Valentina and Domenico Marson and Erik Laurini and Maurizio Fermeglia and Lisa Licitra and Silvana Pilotti and Paolo Bossi and Federica Perrone",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.molonc.2014.09.003",
language = "English",
volume = "9",
pages = "389--397",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Smoothened (SMO) receptor mutations dictate resistance tovismodegib in basal cell carcinoma

AU - Pricl, Sabrina

AU - Cortelazzi, Barbara

AU - Dal Col, Valentina

AU - Marson, Domenico

AU - Laurini, Erik

AU - Fermeglia, Maurizio

AU - Licitra, Lisa

AU - Pilotti, Silvana

AU - Bossi, Paolo

AU - Perrone, Federica

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Basal cell carcinomas (BCCs) and a subset of medulloblastomas are characterized by loss-of-function mutations in the tumor suppressor gene, PTCH1. PTCH1 normally functions by repressing the activity of the Smoothened (SMO) receptor. Inactivating PTCH1 mutations result in constitutive Hedgehog pathway activity through uncontrolled SMO signaling. Targeting this pathway with vismodegib, a novel SMO inhibitor, results in impressive tumor regression in patients harboring genetic defects in this pathway. However, a secondary mutation in SMO has been reported in medulloblastoma patients following relapse on vismodegib to date. This mutation preserves pathway activity, but appears to confer resistance by interfering with drug binding.Here we report for the first time on the molecular mechanisms of resistance to vismodegib in two BCC cases. The first case, showing progression after 2 months of continuous vismodegib (primary resistance), exhibited the new SMO G497W mutation. The second case, showing a complete clinical response after 5 months of treatment and a subsequent progression after 11 months on vismodegib (secondary resistance), exhibited a PTCH1 nonsense mutation in both the pre- and the post-treatment specimens, and the SMO D473Y mutation in the post-treatment specimens only. In silico analysis demonstrated that SMOG497W undergoes a conformational rearrangement resulting in a partial obstruction of the protein drug entry site, whereas the SMO D473Y mutation induces a direct effect on the binding site geometry leading to a total disruption of a stabilizing hydrogen bond network. Thus, the G497W and D473Y SMO mutations may represent two different mechanisms leading to primary and secondary resistance to vismodegib, respectively.

AB - Basal cell carcinomas (BCCs) and a subset of medulloblastomas are characterized by loss-of-function mutations in the tumor suppressor gene, PTCH1. PTCH1 normally functions by repressing the activity of the Smoothened (SMO) receptor. Inactivating PTCH1 mutations result in constitutive Hedgehog pathway activity through uncontrolled SMO signaling. Targeting this pathway with vismodegib, a novel SMO inhibitor, results in impressive tumor regression in patients harboring genetic defects in this pathway. However, a secondary mutation in SMO has been reported in medulloblastoma patients following relapse on vismodegib to date. This mutation preserves pathway activity, but appears to confer resistance by interfering with drug binding.Here we report for the first time on the molecular mechanisms of resistance to vismodegib in two BCC cases. The first case, showing progression after 2 months of continuous vismodegib (primary resistance), exhibited the new SMO G497W mutation. The second case, showing a complete clinical response after 5 months of treatment and a subsequent progression after 11 months on vismodegib (secondary resistance), exhibited a PTCH1 nonsense mutation in both the pre- and the post-treatment specimens, and the SMO D473Y mutation in the post-treatment specimens only. In silico analysis demonstrated that SMOG497W undergoes a conformational rearrangement resulting in a partial obstruction of the protein drug entry site, whereas the SMO D473Y mutation induces a direct effect on the binding site geometry leading to a total disruption of a stabilizing hydrogen bond network. Thus, the G497W and D473Y SMO mutations may represent two different mechanisms leading to primary and secondary resistance to vismodegib, respectively.

KW - Basal cell carcinoma

KW - Hedgehog pathway

KW - Primary resistance

KW - PTCH1

KW - Secondary resistance

KW - SMO

KW - Vismodegib

UR - http://www.scopus.com/inward/record.url?scp=84921351430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921351430&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2014.09.003

DO - 10.1016/j.molonc.2014.09.003

M3 - Article

VL - 9

SP - 389

EP - 397

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 2

ER -